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 SUMMARY 
 
FULL TITLE OF STUDY:   
Tranexamic acid for the treatment of postpartum haemorrhage:   
An international, randomised, double blind, placebo controlled trial 
SHORT  TITLE:                  WORLD MATERNAL ANTIFIBRINOLYTIC TRIAL 
TRIAL ACRONYM:          THE WOMAN  TRIAL 
PROTOCOL NUMBER:   ISRCTN76912190 
EUDRACT NUMBER:    2008-008441-38 CLINICALTRIALS.GOV  ID: NCT00872469 
BACKGROUND: Each year, worldwide about 530,000 women die from causes related to pregnancy and childbirth.  
Almost all (99%) of the deaths are in low and middle income countries.  Obstetric haemorrhage is the leading cause of 
maternal mortality accounting for between one quarter and one third of deaths, most of which occur in the 
postpartum period.  About 14 million mothers develop postpartum haemorrhage (PPH) each year and about 2% of 
them will die, with an average interval from onset to death of about 2 to 4 hours.  Obstetric haemorrhage is also an 
important cause of maternal mortality in high income countries where it accounts for about 13% of maternal deaths. 
Systemic antifibrinolytic agents are widely used in surgery to prevent clot breakdown (fibrinolysis) in order to reduce 
surgical blood loss.  A systematic review of randomised controlled trials of antifibrinolytic agents in surgical patients 
identified 211 randomised controlled trials including 20,781 randomised participants. The results show that 
tranexamic acid (TXA) reduces the risk of blood transfusion by a relative 39% (RR=0.61, 95%CI 0.54 to 0.69). TXA 
reduces transfused volume by 1.1 units (95%CI 0.64 to 1.59). TXA also reduces the need for re-operation due to 
bleeding (RR= 0.67, 95%CI 0.41 to 1.09).  There was no evidence of an increased risk of thrombotic events. 
TXA significantly reduces uterine blood loss in women with menorrhagia and is “recommended for consideration” as a 
treatment in intractable postpartum haemorrhage in the UK.  However, at present there is little reliable evidence from 
randomised trials on the effectiveness of TXA in the treatment of PPH.  A systematic review of randomised trials of 
TXA in PPH conducted by the investigators identified three trials of the prophylactic use of TXA, including a total of 460 
participants.  Although there was a significant reduction in average postpartum blood loss in women treated with TXA, 
the quality of the trials was poor.  None had adequate allocation concealment and even in aggregate the trials were 
too small to assess the effects of TXA on the clinically important end points of mortality, hysterectomy and thrombotic 
side effects.  The most recently updated PPH treatment guidelines prepared by the World Health Organization (WHO) 
state that TXA may be used in the treatment of PPH if other measures fail, but points out that the quality of evidence 
on which this recommendation is based is low and recommends that further clinical trials of TXA in PPH are 
conducted. 
AIM: The WOMAN Trial aims to determine the effect of the early administration of tranexamic acid on mortality, 
hysterectomy and other morbidities (surgical interventions, blood transfusion, risk of non-fatal vascular events) in 
woman with clinically diagnosed postpartum haemorrhage. The use of health services and safety, especially 
thromboembolic effect, on breastfed babies will also be assessed.  
OUTCOME: Outcomes will be collected at 42 days after randomisation, at discharge from randomising hospital or at 
death (whichever occurs first).   
PRIMARY OUTCOME: The primary outcome is the proportion of women who die or undergo hysterectomy. The primary 
cause of death will be described.  
SECONDARY OUTCOMES: 
(a) Death 
(b) Surgical Interventions: including hysterectomy, brace suture (B-Lynch/Cho), selective arterial embolisation, 
laparotomy for other reasons, manual removal of placenta, intrauterine tamponade (packing or gauzing the 
uterine cavity, condom-catheter, any other method of intrauterine tamponade), artery ligation, to achieve 
haemostasis 
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(c) Blood transfusion – blood or blood component units transfused 
(d) Health Status measured using the EQ-5D 
(e) Thromboembolic events (myocardial infarction, strokes, pulmonary embolism, DVT) 
(f) Other relevant medical events 
(g) Length of stay at hospital/time spent at an intensive care unit 
(h) Need for mechanical ventilation 
(i) Status of breastfed baby/ies 
(j) Cost-effectiveness 
TRIAL DESIGN: A large, pragmatic, randomised, double blind, placebo controlled trial among 20,000 women with a 
clinical diagnosis of postpartum haemorrhage 
DIAGNOSIS AND INCLUSION/EXCLUSION CRITERIA:  
 All legally adult women with clinically diagnosed postpartum haemorrhage following vaginal delivery of a baby or 
caesarean section. The clinical diagnosis of PPH may be based on any of the following:  
 estimated blood loss after vaginal delivery of a baby > 500 mL OR  
 >1,000 mL from caesarean section OR   
 blood loss sufficient to compromise the haemodynamic status of the woman 
 The fundamental eligibility criterion is the responsible clinician’s ‘uncertainty’ as to whether or not to use an 
antifibrinolytic agent in a particular woman with postpartum haemorrhage.  
 Women for whom the responsible doctor considers there is a clear indication for antifibrinolytic therapy 
should not be randomised.  
 Women for whom there is considered to be a clear contraindication to antifibrinolytic therapy should not be 
randomised.  
 Where the responsible clinician is substantially uncertain as to the appropriateness of antifibrinolytic agents in a 
particular woman with PPH. 
 There are no other pre-specified exclusion criteria. 
TEST PRODUCT, REFERENCE THERAPY, DOSE AND MODE OF ADMINISTRATION: A dose of tranexamic acid (1 gram by intravenous 
injection) or placebo (sodium chloride 0.9%) will be given as soon as possible after randomisation.  If after 30 minutes 
bleeding continues, or if it stops and restarts within 24 hours after the first dose, a second dose may be given. 
SETTING: This trial will be coordinated from the London School of Hygiene & Tropical Medicine (University of London) 
and conducted worldwide in hospitals in low, middle and high income countries. It is likely that most patient 
recruitment will be in countries with high rates of mortality and morbidity from postpartum haemorrhage. 
DURATION OF TREATMENT AND PARTICIPATION:  The first dose will be given immediately after randomisation. If required, the 
second dose will be given up to 24 hours after the first dose. No further trial treatment will be given. Participation will 
end at discharge from randomising hospital, death or at 42 days post randomisation whichever occurs first. 
CRITERIA FOR EVALUATION: All patients randomly assigned to one of the treatments will be analysed together, regardless 
of whether or not they completed or received that treatment, on an intention to treat basis. 
CLINICAL PHASE: 3 
PLANNED TRIAL START: May 2009 
PLANNED DATE OF LAST PATIENT ENROLMENT: 31 March 2016 PLANNED DATE OF LAST OUTCOME 12 May 2016 
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 1  INTRODUCTION 
 
 
Each year, worldwide, about 530,000 women die from causes related to pregnancy and childbirth. Nearly all (99%) of 
these deaths are in low and middle income countries.1  Haemorrhage, which usually occurs in the postpartum period, 
is responsible for between one quarter and one third of obstetric deaths.2  
 
Postpartum haemorrhage (PPH) is commonly defined as blood loss of >500mL after vaginal delivery of a baby, or 
>1000mL after caesarean section. However, these thresholds do not take into account pre-existing health status, and 
blood loss of as little as 200mL can be life-threatening for a woman with severe anaemia or cardiac disease.3 
 
Of the 14 million women who have PPH each year, about 2% die, with an average interval from onset of bleeding to 
death of 2 to 4 hours.2  Although many deaths from PPH occur outside healthcare facilities, a significant number occur 
in hospital, where effective emergency care has the potential to save lives.4,5 PPH is also an important cause of 
maternal mortality in high income countries, accounting for about 13% of maternal deaths.6 
 
PPH also causes hospital morbidity. Many women require blood transfusion which sometimes can transmit blood 
borne viral infections. Approximately 1% of women with spontaneous vaginal deliveries require transfusion, but the 
figure increases to 5% or 6% for women with instrumental deliveries or caesarean sections.7  The risk of infection from 
transfused blood is considerably higher in countries that do not screen all blood for transfusion.8  In high income 
countries the risk of transfusion transmitted infection is low, but adverse reactions related to blood transfusion are 
common.9  
 
Severe anaemia is a common consequence of PPH and affects about 11% of the 14 million women with PPH each 
year.10  Severe anaemia can cause disabling fatigue and seriously reduce a woman’s capacity to look after her children 
and to work.11   
 
Systemic antifibrinolytic agents are widely used in surgery to prevent clot breakdown (fibrinolysis) in order to reduce 
surgical blood loss. A systematic review of randomised controlled trials of antifibrinolytic agents in surgical patients 
identified 211 randomised controlled trials including 20,781 randomised participants. The results show that 
tranexamic acid (TXA) reduces the risk of blood transfusion by a relative 39% (RR=0.61, 95%CI 0.54 to 0.69). In all 
patients, TXA reduces transfused volume by 1.1 units (95%CI 0.64 to 1.59). TXA may also reduce the need for re-
operation due to bleeding (RR=0.67, 95%CI 0.41 to 1.09). There was no evidence of an increased risk of thrombotic 
events.18 
 
TXA significantly reduces uterine blood loss in women with menorrhagia and is “recommended for consideration” as a 
treatment in intractable postpartum haemorrhage in the UK.19  However, at present there is little reliable evidence 
from randomised trials on the effectiveness of TXA in the treatment of PPH. A systematic review of randomised trials 
of TXA in PPH conducted by the investigators identified three trials of the prophylactic use of TXA, including a total of 
460 participants.20  Although there was a statistically significant reduction in average postpartum blood loss in women 
treated with TXA [weighted mean reduction of approximately 100 mL] the quality of the trials was poor. None had 
adequate allocation concealment and even in aggregate the trials were too small to assess the effects of TXA on the 
clinically important end points of mortality, hysterectomy and thrombotic side effects. The most recently updated PPH 
treatment guidelines prepared by the World Health Organization (WHO) state that TXA may be used in the treatment 
of PPH if other measures fail, but points out that the quality of evidence on which this recommendation is based is low 
and recommends that further clinical trials of TXA in PPH are conducted. 
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1.1 NEED FOR A TRIAL  
 
The WOMAN Trial will provide a reliable scientific basis for recommendations as to whether or not tranexamic acid 
should be used in the treatment of PPH. If TXA reduces mortality in women with PPH, this would be of considerable 
significance worldwide. There is a global commitment to the Millennium Development Goal (MDG) of reducing 
maternal deaths by three-quarters by the year 2015, a commitment that requires a reduction of the maternal 
mortality ratio by 5.5% each year. Because maternal haemorrhage accounts for over a quarter of deaths, an effective 
treatment for PPH would contribute importantly to the MDG of reducing maternal mortality. TXA might also reduce 
the need for hysterectomy, decrease the risk of anaemia and avoid the need for blood transfusion. Blood is a scarce 
resource in many countries with a risk of transfusion transmitted infections. If TXA was effective in the hospital 
setting, further research could be conducted to evaluate its use in the community, possibly including the use of oral 
rather than intravenous administration.   
 
The results of this trial will be disseminated by publication in peer reviewed medical journals, conference 
presentations, and in an updated version of the Cochrane systematic review of treatments for postpartum bleeding. 
There is evidence that hospitals participating in multi-centre trials are more likely to implement the trial results.21  For 
this reason, a large international multi-centre trial like the WOMAN trial can be expected to have a substantial impact 
on clinical practice. The large network of collaborating sites will ensure that the results are disseminated worldwide. 
 
1.2 TRANEXAMIC ACID AND ITS EFFECT ON BLEEDING  
 
In the haemostatic process, coagulation occurs rapidly at the site of a damaged vessel building a tight net of fibrin, 
while at the same time, the fibrinolytic system removes the fibrin deposits that could cause permanent vascular 
occlusion once vascular repair has taken place.22  The coagulation and fibrinolytic system are believed to be in a state 
of dynamic balance which maintains an intact vascular system.  Tranexamic acid is a potent antifibrinolytic agent that 
exerts its effect by blocking lysine binding sites on plasminogen molecules and has the potential to enhance the 
effectiveness of the patient’s own haemostatic mechanisms.  Consequently, clot breakdown (fibrinolysis) is inhibited 
and excessive or recurrent bleeding is reduced.  
 
During delivery, when the placenta separates from the uterine wall, a sequence of physiologic and haemostatic 
changes occur that reduce bleeding: strong myometrial contractions, increased platelet activity, a massive release of 
coagulant factors and a parallel increase in the fibrinolytic activity.23  As a result, there is a theoretical rationale for the 
use of  antifibrinolytic agents in the treatment of postpartum haemorrhage.18,24,25 
 
1.3 POTENTIAL SIDE EFFECTS OF TRANEXAMIC ACID 
 
As TXA inhibits the breakdown of fibrin deposits already formed, it might theoretically increase the risk of 
thromboembolism.  However, the systematic review of TXA in surgery did not show statistically significant increases in 
the risks of any of the thromboembolic events assessed.14  
 
Events 
Effect of TXA 
RR 95% CI 
Myocardial Infarction 0.96 0.48-1.90 
Stroke 1.25 0.47-3.31 
Deep venous thrombosis 0.77 0.37-1.61 
Renal failure 0.73 0.16-3.32 
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During pregnancy, women have an increased risk of thromboembolic events, compared with non-pregnant women.  
The absolute risk of symptomatic venous thrombosis during pregnancy has been estimated to be between 0.5 and 3.0 
per 1,000 women based on studies using radiographic documentation.26-28  Studies using objective criteria for 
diagnosis have found that ante-partum deep vein thrombosis (DVT) is as common as postpartum thrombosis and 
occurs with equal frequency in all three trimesters.26  
 
A population-based cohort study estimated an incidence of thromboembolic events to be 200 per 100,000 woman-
years.29  DVT was three times more common than pulmonary embolism and thromboembolic events were five times 
more likely in the postpartum period than during the pregnancy. This was particularly evident with pulmonary 
embolism which was 15 times more likely to occur in the postpartum period than during the pregnancy. 
Thromboembolic events will be collected routinely as part of the data collection process for this trial.  
 
TXA passes into breast milk in very low concentrations, approximately one hundredth of the concentration in the 
maternal blood. An antifibrinolytic effect in the infant is very unlikely at this low concentration.30  The 
thromboembolic effects on breastfed babies will be assessed in this trial.    
 
TXA is not a new drug and is generally well tolerated.  Adverse events are uncommon and usually manifest as nausea 
or diarrhoea, or occasionally as orthostatic reactions.18 
 
 
1.4 OBJECTIVE  
 
The WOMAN trial will provide reliable evidence as to whether the antifibrinolytic agent tranexamic acid reduces 
mortality, hysterectomy and other morbidities in woman with clinically diagnosed postpartum haemorrhage. 
Thromboembolic effects on breastfed babies will be assessed. 
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2 TRIAL DESIGN 
 
2.1 OVERVIEW 
 
This trial is a large, pragmatic, randomised, double blind, placebo controlled trial to quantify the effects of the early 
administration of tranexamic acid on death, hysterectomy and other relevant outcomes.  20,000 adult women, who 
have clinically diagnosed postpartum haemorrhage and who fulfil the eligibility criteria, will be randomised to receive 
either TXA or placebo. The eligibility criteria are based on the uncertainty principle. 
 
Pragmatic design and the uncertainty principle:  The pragmatic design will allow us to find out how effective the 
treatment actually is in routine everyday practice. The eligibility criteria are based on the uncertainty principle. This 
approach to trial eligibility is well established.31  A patient can be enrolled if, and only if, the responsible clinician is 
substantially uncertain as to which of the trial treatments would be most appropriate for that particular woman (see 
graph 1).  A woman should not be enrolled if the responsible clinician or the woman (or her representative) are for 
any medical or non-medical reasons reasonably certain that one of the treatments that might be allocated would be 
inappropriate for this particular individual (in comparison with either no treatment or some other treatment that 
could be offered to the patient in or outside the trial).  Using the uncertainty principle should allow the process of this 
trial to be closer to what is appropriate in normal medical practice. Clinicians, women and their representatives will be 
provided with information about the trial treatment to assist them in their judgement.  
 
Randomisation: Women eligible for inclusion should be randomised, and the study treatment started, as soon as 
possible. The Entry form (Appendix 1) will be used to assess eligibility and collect baseline information. The next 
consecutively numbered treatment pack, taken from a box of eight packs, should be chosen.  Once a patient has been 
randomised, the outcome in hospital needs to be collected even if the trial treatment is interrupted or is not actually 
given. 
 
Follow-up: No extra tests are required for the trial but a short Outcome form (Appendix 2) must be completed directly 
from the medical records six weeks (42 days) after randomisation or on discharge from the randomising hospital or on 
death (whichever occurs first).  Any adverse events which become known to the investigator will be reported up to 42 
days after randomisation.  
 
2.2 SETTINGS 
 
The pragmatic nature of this trial will allow for the recruitment of women from a wide variety of health care facilities.  
Participating hospitals or maternal health facilities will be selected from high, middle and low income countries. 
Eligible women may have delivered their babies at the participating hospital or may have delivered outside the 
participating hospital and been admitted following the delivery of a baby. There is no limit to the maximum number of 
women to be recruited at each site. 
 
2.3 NUMBER OF PATIENTS NEEDED 
 
Two main factors determine the number of patients needed in a trial. These are the estimated event rate and size of 
the treatment effect. 
 
Estimated event rate: Review of the literature and data from hospital reports shows that there are wide variations in 
mortality after PPH worldwide, varying from about 0.6% in the United Kingdom to 2.6% in South Africa and 20% in 
some parts of Africa. The frequency of occurrence of peripartum hysterectomies also varies, from about 0.02% in the 
United Kingdom to 2% in Nigeria or 14% in Congo-Brazzaville.  Based on these ranges, a baseline event rate of 2.5% for 
mortality and 2.5% for hysterectomy might reasonably be expected. 
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Sample size and size of treatment effect that should be detectable: 
Assuming a control group event rate of 2.5% for mortality and 2.5% for hysterectomy with 1% of women having both a 
hysterectomy and then dying, a study with 15,000 women would have over 90% power (two sided alpha=5%) to 
detect a clinically important 25% reduction from 4% to 3% in the primary endpoint of mortality or hysterectomy. A 
survey of baseline event rates among hospitals that have expressed interest in taking part shows that baseline event 
rates of this magnitude are realistic and that higher baseline event rates might reasonably be expected. Experience 
from the CRASH-1 and CRASH-2 clinical trials suggests that the anticipated rates of loss to follow-up (less than 1%) 
would not impact importantly on study power. 
 
Additional information for justification to changes made in Version 1.1  
Summary of amendment: As of December 2013, the trial has recruited 10,014 women, 261 of whom died. Because 
the effect of tranexamic acid on maternal mortality is of considerable public health importance, the sample size has 
been increase from 15,000 to 20,000 so that the trial has enough power to detect an effect on this important 
secondary outcome. This involves an additional 15 months of recruitment. On this basis, the Trial Protocol Version 1.0, 
dated 11 May 2009, has been modified as follows: 
 Increase the sample size from 15,000 to 20,000 
 Date of last patient recruitment: changes from 31 December 2014 to 31 March 2016  
 Date of last patient follow up: changes from 11 February 2015 to 12 May 2016 
Rationale: If the administration of tranexamic acid were shown reliably to reduce mortality and morbidity in women 
with postpartum haemorrhage (PPH), it would be a major obstetric advance with the potential to improve the lives of 
tens of thousands of women around the world. Tranexamic acid is inexpensive, heat stable and easy to use and could 
be rapidly implemented if shown to be effective. The challenge for research is to provide reliable evidence of 
effectiveness and safety. Although PPH is a leading cause of maternal mortality, the case-fatality rate is relatively low, 
which means that trials of treatments to reduce maternal mortality have to recruit thousands of patients in order to 
have enough power to detect a reduction in the risk of death. The primary end point in the WOMAN trial is a 
composite of death or hysterectomy. Use of a composite end point is justified by the assumption that the effect of the 
trial treatment on death and hysterectomy is likely to be similar and that patients will attach importance to each of 
the components. As of December 2013, the trial has recruited 10,014 women (261 of whom died). The primary end 
point (death or hysterectomy) occurs in approximately 6.3% of recruited women and a trial of 15,000 women should 
have enough power to reliably detect a 25% reduction in death or hysterectomy.  
 
Although the use of a composite end point increases the statistical power of the trial, if the effect of TXA on death and 
hysterectomy are not similar, it could make the interpretation of the results more difficult. If the trial had enough 
power to detect a reduction in maternal mortality alone, this would be an important advantage. Because the case-
fatality rate observed in the trial is higher than expected (3%), a modest increase in the sample size from 15,000 to 
20,000 women will mean that the trial will have sufficient (90%) power to detect a 25% reduction in maternal 
mortality. Such an increase would also provide additional power to detect an effect on the composite end point of 
death or hysterectomy, whilst providing protection against the possibility that the effect of tranexamic acid on death 
and hysterectomy is different. Based on current recruitment, increasing the sample size from 15,000 to 20,000 women 
will involve an additional 15 months of recruitment. Given the global public health importance of reducing maternal 
mortality, we believe that this extra effort is justified.   
  
2.4 RECRUITMENT OF COLLABORATING INVESTIGATORS 
 
The trial will recruit collaborating sites from all countries worldwide and will continue to add sites to ensure the 
sample size is achieved.  Suitable collaborating sites and investigators will be assessed on the level of obstetric service 
they provide and their ability to conduct the trial.  In advance of the trial starting at a site the Principal Investigator 
must agree to adhere to Good Clinical Practice Guidelines and all relevant regulations in their country.  In addition, all 
relevant regulatory and ethics approvals will need to be in place. 
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2.5 ELIGIBILITY 
 
Immediately after delivery of the baby/ies, all usual care should be given for the prevention of PPH.  Some bleeding is 
expected after delivery.  However, if bleeding continues and a diagnosis of PPH is made, all usual treatments should 
be given and at the same time the assessment for inclusion in the trial should be made.  It is important to consider 
inclusion as early as possible. 
 
Inclusion criteria:  
All legally adult women with clinically diagnosed postpartum haemorrhage following vaginal delivery of a baby or 
caesarean section; women may have delivered their babies at a participating hospital or outside a participating 
hospital, with hospital admission following delivery: 
 where the responsible clinician is substantially uncertain as to whether or not to use TXA 
 when consent has been given according to approved procedures 
 
The clinical diagnosis of PPH may be based on any of the following:  
 estimated blood loss after vaginal delivery of a baby > 500 mL OR  
 >1000 mL from caesarean section OR   
 estimated blood loss enough to compromise the haemodynamic status of the woman  
 
Exclusion criteria: 
 Women for whom the responsible clinician considers there is a clear indication for TXA should not be randomised. 
 Women for whom the responsible clinician considers there is a clear contraindication for TXA should not be 
randomised (e.g. a known thromboembolic event during pregnancy). 
 
The fundamental eligibility criterion is the responsible clinician’s ‘uncertainty’ as to whether or not to use an 
antifibrinolytic agent in a particular woman with postpartum haemorrhage.  
 
The TXA summary of product characteristics30 and an Investigator’s Brochure will be provided to investigators to 
ensure they have adequate information when considering the risk-benefit and the appropriateness of the trial for 
each woman. 
 
Graph 1: Eligibility  
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2.6 CONSENT AND ETHICAL CONSIDERATIONS 
 
This trial will be carried out worldwide and will include women soon after delivery of a baby.  Postpartum 
haemorrhage is an emergency situation and clinical activities will be directed towards the provision of emergency 
care.  Eligible women have a life threatening condition.  Furthermore, their physical, mental and emotional state may 
be altered as a result of their blood loss or labour pains or by drugs administered during the labour.  The consent 
process in this situation requires careful consideration bearing in mind applicable regulatory requirements, adherence 
to ICH-GCP and the requirements in the Declaration of Helsinki. 
 
Advance Information: The majority of women deliver without complications and it would not be in the best interest 
of all pregnant women to cause undue concern by providing detailed information about this trial in the 
antenatal/delivery period.  Also, it is not possible to identify in advance those women who will go on to develop PPH, 
and obtain advance consent. Therefore, where possible, a summary of the trial information will be provided to 
pregnant women (Appendix 3a).  Refusal to be considered for participation will be documented in the woman’s 
medical records and her decision respected. 
 
Following delivery of her baby, and once a woman has been diagnosed with PPH, a critical clinical emergency situation 
exists. The risk of death is highest early after delivery. The process by which information will be given and consent 
obtained will depend on the need for urgent clinical intervention and her physical, mental and emotional state.  Also, 
the availability and ability of a personal representative to make a decision on the woman’s behalf will have to be taken 
into consideration. The approach which will allow the woman to have the most input into the decision making process 
without endangering her life will be utilised: 
 
a) The woman is fully competent: The woman will be approached with the agreement of the primary carer (the 
midwife or doctor) at the time of diagnosis. Factors which may impair her decision making process including pain, 
altered level of consciousness due to drugs given and degree of blood loss, will be taken into consideration. An 
Information Sheet (Appendix 3c) will be provided and the study will be discussed with her and a written consent 
obtained (Appendix 3d). If the woman is unable to read or write, then the information sheet may be read to her and 
she may then mark the consent form with either a cross or thumbprint.  In this event, a witness NOT associated with 
the trial, must provide a full signature confirming the mark. 
 
b) The woman’s mental capacity is impaired and either a Personal or Professional representative is available:  
Information should be given to the woman taking her level of mental impairment into consideration.  Oral refusal by 
the woman should be respected and she should not be enrolled.   
a. If a Personal Representative (PeR) who is knowledgeable about the woman’s values and beliefs is available, an 
Information Sheet will be provided.  Opportunity for questions should be given and written consent obtained.  If 
the PeR is unable to read or write, then the information sheet may be read to him/her and a mark with either a 
cross or thumbprint made on the consent form.  In this event, a witness NOT associated with the trial, must 
provide a full signature confirming the mark. 
b. If a Personal Representative is not available and the woman is unable to provide valid informed consent, then an 
independent doctor / midwife / other site staff allowed to fulfil this role (ideally the primary carer if s/he is not 
part of the trial team) may be asked to consent as a Professional Representative (PrR).  Informed consent given 
by a representative shall represent the woman’s presumed will. 
 
c) The woman’s mental capacity is impaired and neither a Personal nor Professional representative is available: In 
situations where the woman is facing a clinical emergency and no PeR/PrR is available, the investigator and ONE 
independent person (doctor or midwife) who is not participating in this trial may enrol the woman into the trial by 
certifying in writing in the woman’s medical records that: 
 the woman is facing a life-threatening postpartum haemorrhage; 
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 the woman is unable to give her consent as a result of her medical condition; 
 it is not feasible to contact the woman’s PeR/PrR to obtain consent within the window period; and 
 neither the woman nor the woman’s PeR/PrR nor any member of the family has informed the investigator of 
any objections to the woman being used as a participant in this trial. 
 
For women enrolled under such emergency consent procedure, the woman or her PeR or PrR should be informed 
about the trial as soon as it is possible and asked to consent for continuation of any trial procedure.  A summary 
overview of the consent procedure is provided in Appendix 3b. 
 
The requirements of the relevant ethics committee will be adhered to at all times.  
 
2.7 RANDOMISATION 
 
Randomisation codes will be generated and secured by an independent statistical consultant from Sealed Envelope 
Ltd (UK). The codes will be made available to Brecon Pharmaceuticals Limited (UK) explicitly for the treatment packs to 
be created in accordance with the randomisation list. Eligibility will be determined from the routinely collected clinical 
information and no trial-specific tests are required. Women eligible for inclusion should be randomised to receive 
either active (tranexamic acid) or placebo (sodium chloride 0.9%) treatment and the trial treatment started as soon as 
possible.  
 
Baseline information will be collected on the trial entry form and the next lowest consecutively numbered pack will be 
taken from a box of eight treatment packs. When the treatment ampoule is confirmed as being intact, at this point the 
patient is considered to be randomised onto the trial. The entry form data will be sent to the Trial Coordinating Centre 
as soon as possible. Once a patient has been randomised, the outcome of the woman should be obtained even if the 
trial treatment is interrupted or is not actually given. 
 
2.8 TREATMENT 
 
Tranexamic acid will be compared with matching placebo (sodium chloride 0.9%). 
 
2.8.1 DOSE SELECTION 
 
In randomised trials of antifibrinolytic agents in surgery, TXA dose regimens vary widely. Loading doses range 
from 2.5 mg/kg to 100 mg/kg and maintenance doses from 0.25 mg/kg/hour to 4 mg/kg/hour given over periods 
of one to twelve hours.  Studies examining the impact of different doses of tranexamic acid on bleeding and 
transfusion requirements showed no significant differences between a high dose and a low dose.  Studies in 
cardiac surgery have shown that a 10 mg/kg initial dose of TXA followed by an infusion of 1 mg/kg/hour produces 
plasma concentrations sufficient to inhibit fibrinolysis in vitro.  Horrow et al (1995) examined the dose-response 
relationship of TXA and concluded that 10 mg/kg followed by 1 mg/kg/hour decreases bleeding in cardiac 
surgery, but larger doses did not provide any additional haemostatic benefit.32  Trials of the use of TXA for the 
prevention of obstetric haemorrhage used TXA at a dose of 1 gram without major complications.20   
 
In the emergency situation, the administration of a fixed dose is more practicable since weighing women with 
PPH would be difficult. Therefore, a fixed dose of 1 gram of TXA initially followed by 1 gram if bleeding continues, 
which is within the dose range which has been shown to inhibit fibrinolysis and provide haemostatic benefit, has 
been selected for the WOMAN trial. On the basis of experience in surgery, the dose selected would be efficacious 
for larger patients (>100 kg) but also safe in smaller patients (<50 kg), as the estimated dose/kg that the patients 
in the latter group would receive has been applied in other trials without significant adverse effects. 
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2.8.2 DRUG MANUFACTURE, BLINDING AND SUPPLY OF TRIAL TREATMENT 
 
The active trial drug tranexamic acid (Cyklokapron® Injection) will be purchased on the open market in the UK. 
TXA is manufactured by Pfizer Ltd under Marketing Authorisation Number: PL 00032/0314. The Marketing 
Authorisation guarantees that the product has been manufactured and released in accordance with the United 
Kingdom’s Good Manufacturing Regulations.  
 
Placebo (sodium chloride 0.9%) will be manufactured specially to match the tranexamic acid by South Devon 
Healthcare NHS Trust, Kemmings Close, Paignton, Devon, TQ4 7TW, under UK Manufacturer’s authorisation 
Number: MS13079 / MA(IMP) 13079.  
 
Ampoules and packaging will be identical in appearance. The blinding process and first stage Qualified Person 
(QP) release will be done by Brecon Pharmaceuticals Limited, Wye Valley Business Park, Hay-on-Wye, Hereford 
HR3 5PG, under UK Manufacturer’s authorisation Number MIA 11724/MIA IMP 11724.  The blinding process will 
involve complete removal of the original manufacturer’s label and replacement with the clinical trial label 
bearing the randomisation number which will be used as the pack identification. Other pack label text will be 
identical for both TXA and placebo treatments and will be in compliance with requirements for investigational 
medicinal products. Treatment packs containing TXA and placebo will be packed in balanced blocks of 8 (4 TXA: 
4 Placebo) into a box in random order.  
 
Brecon Pharmaceuticals Limited will also be responsible for maintaining the Product Specification File (PSF) until 
final database lock and unblinding of the trial data. Quality control checks to assure blinding process will be 
performed on a random sample of final QP released drug packs. High Performance Liquid Chromatography 
analyses (HPLC) separation of known tranexamic acid will be assessed against blinded samples to confirm which 
ampoule contains the placebo and active treatments. The tested samples will be unblinded to assure accuracy of 
blinding.   
 
The Trials Coordinating Centre (TCC) will be responsible for assuring all relevant approvals are available at the 
TCC before release of the trial treatment to a site. 
 
2.8.3 ADMINISTRATION OF TRIAL TREATMENT 
 
Each treatment pack will contain: 
 4 x 500mg ampoules of tranexamic acid or placebo 
 2 x sterile 10mL syringe and 21FG needle 
 Stickers (for attaching to data forms and patient medical records) 
 
TREATMENT AMPOULES 
DOSE (TRANEXAMIC 
ACID OR PLACEBO) 
ADMINISTRATION INSTRUCTION 
DOSE 1 2 1 gram 
To be administered by intravenous injection at an 
approximate rate of 1 mL/minute to all randomised women 
as soon as possible after randomisation. 
DOSE 2 2 1 gram 
If after 30 minutes bleeding continues, or if it stops and 
restarts within the 24 hours after the first dose, a second 
dose may be given. To be administered by intravenous 
injection at an approximate rate of 1 mL/minute. 
The trial treatment injections should not be mixed with blood for transfusion, or infusion solutions containing 
penicillin or mannitol. 
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2.8.4 OTHER TREATMENTS FOR PPH 
 
There is a wide spectrum of first and second line treatments of postpartum haemorrhage. As the trial will be 
conducted worldwide, each participating site should follow its own clinical guidelines for the treatment of 
postpartum haemorrhage. Information on other treatments given will be collected on the outcome form. 
Tranexamic acid or placebo would be an additional treatment to the routine management of postpartum 
haemorrhage.  
 
2.9 ADVERSE EVENTS (AEs) 
 
TXA has a well documented safety profile. No increase in thromboembolic risks associated with its use has been 
shown to date. However, as discussed in Section 1.3 an expected complication of pregnancy is an increased risk of 
thromboembolic events. This trial will collect data on all thromboembolic events as secondary outcomes, and all such 
events are routinely reported to the independent data monitoring committee (DMC) for unblinded review. 
 
Definitions:  
Adverse event (AE)  
Any untoward medical occurrence affecting a trial participant during the course of a clinical trial  
 
Serious Adverse Event (SAE)  
A serious adverse event (experience) is any untoward medical occurrence that at any dose 
 results in death; 
 is life-threatening; 
 requires inpatient hospitalisation or prolongation of existing hospitalisation; 
 results in persistent or significant disability/incapacity; or 
 is a congenital anomaly/birth defect. 
 
Adverse Reaction (AR)  
An adverse event when there is at least a possibility that it is causally linked to a trial drug or intervention 
  
Serious Adverse Reaction (SAR)  
SAE that is thought to be causally linked to a trial drug or intervention 
  
Suspected Unexpected Serious Adverse Reaction (SUSAR)  
An unexpected occurrence of a SAR; there need only be an index of suspicion that the event is a previously unreported 
reaction to a trial drug or a previously reported but exaggerated or unexpectedly frequent adverse drug reaction. 
 
Reporting of Adverse Events for this trial: Death, life-threatening complications and prolonged hospital stay are pre-
specified outcomes to be reported in this trial and also to the independent data monitoring committee. This clinical 
trial is being conducted in a critical emergency condition, using a drug in common use. It is important to consider the 
natural history of the critical medical event affecting each woman enrolled, the expected complications of this event 
and the relevance of the complications to TXA.   
 
Adverse events to be reported using an adverse event reporting form will be limited to those NOT already listed as 
primary or secondary outcomes, yet, which might reasonably occur as a consequence of the trial drug. Events that are 
part of the natural history of the primary event of PPH or expected complications of PPH should not be reported as 
adverse events. 
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In addition, if a woman is discharged from the randomising hospital before day 42 and is readmitted to hospital, 
requires medical care for any reason or is known to have died, an ‘adverse event form’ should be completed 
irrespective of the cause. 
 
If a Serious Adverse Event occurs, this should be logged by calling the Trial Coordinating Centre Emergency Helpline 
and a written report submitted within 24 hours. The TCC will coordinate the reporting of all SAEs to all relevant 
Regulatory Agencies, Ethics Committees and local investigators as per local legal requirements. 
 
2.10 UNBLINDING 
 
In general there should be no need to unblind the allocated treatment.  If some contraindication to antifibrinolytic 
therapy develops after randomisation, e.g. clinical evidence of thrombosis, the trial treatment should simply be 
stopped and all usual standard care given. Unblinding should be done only in those rare cases when the clinician 
believes that clinical management depends importantly upon knowledge of whether the patient received 
antifibrinolytic or placebo.  In those few cases when urgent unblinding is considered necessary, a 24-hour telephone 
service will be available and details provided in the Investigator’s Study File and wall posters. The caller will be told 
whether the patient received antifibrinolytic or placebo. An unblinding report form should be completed by the 
investigator. 
 
2.11 MEASURES OF OUTCOME 
 
After a patient has been randomised, outcome in hospital will be collected even if the trial treatment is interrupted or 
is not actually given. No extra tests are required but a short single page Outcome Form will be completed 6 weeks (42 
days) after randomisation, at discharge from the randomising hospital or at death (whichever occurs first).   
 
Primary Outcome: The primary outcome is the proportion of women who die or undergo hysterectomy. The primary 
cause of death will be described.  
 
Secondary outcomes: 
(a) Death  
(b) Surgical Interventions including hysterectomy; brace suture (B-Lynch/Cho); selective arterial embolisation; 
laparotomy for other reasons; manual removal of placenta; intrauterine tamponade (packing or gauzing the 
uterine cavity, condom-catheter, any other method of intrauterine tamponade); artery ligation, to achieve 
haemostasis. 
(c) Blood transfusion – blood or blood component units transfused 
(d) Health Related Quality of life (HRQoL) will be measured by the proxy version of the EQ-5D at discharge from the 
randomising hospital or in hospital at 42 days after randomisation. The EQ-5D includes single item measures of 
mobility, self-care, usual activities, pain/discomfort and anxiety/depression.  Each item is coded using 3 levels  
(1 = no problems; 2 = some problems; 3 = severe problems). The instrument includes a global rating of current 
health using a visual analogue scale (VAS) ranging from 0 (worst imaginable) to 100 (best imaginable). The EQ-5D 
is a  generic measure of health status that provides a simple descriptive profile and a single index value that can 
be used in the clinical and economic evaluation of health care. 
(e) Thromboembolic events (myocardial infarction, strokes, pulmonary embolism, deep vein thrombosis) 
(f) Medical events including renal failure, Adult Respiratory Distress Syndrome, hypertensive disorders of pregnancy 
(including HELLP Syndrome, eclampsia, toxaemia of pregnancy) and other adverse events reported 
(g) Length of stay at hospital / time spent at an intensive care unit 
(h) Receipt of mechanical ventilation 
Page 15 of 36 
Version 1.1 Protocol ISRCTN76912190 Version date: 31 January 2014 
(i) Status of baby/ies: The health status of the baby/ies will be ascertained and information collected on any 
thromboembolic events in breastfed babies 
(j) Cost-effectiveness analysis:  An economic analysis will be relevant if TXA clearly demonstrates efficacy in 
achieving its clinical aims.  In this case, the study will be undertaken in the form of a cost-effectiveness analysis 
with the aim of estimating the incremental cost-effectiveness ratio comparing the use of TXA with normal clinical 
practice.  Analysis will be based on adjusted life years gained.  A further analysis will explore the use of the EQ-5D 
data to quality adjust survival.  In this study, the economic analysis is clearly bounded as virtually all significant 
resource use will occur in the initial period of hospitalisation.  As such, neither a long-term resource analysis nor 
an analysis of out of hospital costs will be required.  The trial use of TXA is likely to mirror its use in normal clinical 
practice, hence the cost-effectiveness estimated in the trial (adjusted for protocol driven costs) will closely 
approximate cost-effectiveness in actual clinical practice.  Data on physical resource consumption (e.g. length and 
nature of hospital stay) will be collected for each patient and a common unit cost at a country level will be 
applied.  A sensitivity analysis will be undertaken to assess the robustness of the economic analysis in response to 
variations in key variables such as drug prices.  In all cases, the economic analysis will be integrated with the 
clinical trial procedures to optimise efficiency and minimise inconvenience to patients. 
 
2.12 DATA COLLECTION 
 
This trial will be coordinated from LSHTM and conducted in hospitals in low, middle and high income countries. Most 
recruitment will be in countries with high rates of mortality and morbidity from postpartum haemorrhage. Data will 
be collected at each site by local investigators and transmitted to the TCC. Only data outlined on the entry, outcome 
and adverse event forms will be collected for this trial.  
 
Relevant data on an entry form will be collected before randomisation to assess eligibility and the form completed if 
randomised.  The outcome form should be completed at death, discharge from the randomising hospital or 6 weeks 
(42 days) after randomisation whichever occurs first. This data should be collected from the woman’s and her 
baby/ies routine medical records as no special tests are required. 
 
If the woman (or her PeR or PrR) withdraws a previously given informed consent or refuses to consent for 
continuation in the trial, or if the woman dies and no consent is available from either a PeR/PrR, her data will be 
handled as follows: 
 Data collected to the point of withdrawal of consent will be used as part of the intention to treat analysis 
 All relevant adverse events identified will be reported as required to all relevant authorities 
 
To allow for variation in available technology for data transfer a variety of methods will be used in this trial. Data will 
be collected by the investigator on paper case report forms (CRFs) and transmitted to the TCC either as a paper form 
(by fax or email) or by entering the data directly into the trial database. Data can also be transmitted by entry onto 
electronic data files which can be emailed or uploaded to the TCC secure web server. In cases where electronic data 
files are used, data stored on the investigator’s computer(s) and data during transfer will be secured by encryption. 
The data will be used in accordance with local law and ethics committee approval.  
 
2.13 MONITORING 
 
GCP section 5.18.3 states in regard to monitoring, “The determination of the extent and nature of monitoring should 
be based on considerations such as the objective, purpose, design, complexity, blinding, size and endpoints of the trial. 
In general there is a need for on-site monitoring, before, during, and after the trial; however in exceptional 
circumstances the sponsor may determine that central monitoring in conjunction with procedures such as investigators 
Page 16 of 36 
Version 1.1 Protocol ISRCTN76912190 Version date: 31 January 2014 
training and meetings, and extensive written guidance can assure appropriate conduct of the trial in accordance with 
GCP. Statistically controlled sampling may be an acceptable method for selecting the data to be verified.” 
This trial is a large, pragmatic, randomised placebo controlled trial. The intervention (tranexamic acid) has marketing 
authorisation in many countries and has been in clinical use for over 40 years. Its safety profile is well established and 
no significant serious adverse events associated with its use have been identified. The trial will routinely collect data 
on adverse events which may theoretically be associated with this product and the condition under investigation, and 
these will be reviewed routinely by the independent Data Monitoring Committee (DMC). Other than consent, the 
administration of the trial drug using a routine clinical procedure and collecting routine clinical information from the 
medical records, there are no complex procedures or interventions for the participants or investigators in this trial. 
Clinical management for underlying conditions will remain as per each hospital’s standard protocol. Based on these 
factors, the probability of harm or injury (physical, psychological, social or economic) occurring as a result of 
participation in this research study has been assessed as low risk to participants in each of these categories.  Based on 
the low risks associated with this trial, a Monitoring Plan to assure appropriate conduct of the trial will be developed 
which will incorporate 100% central monitoring in conjunction with procedures such as investigator training and 
meetings and written guidance. In addition, all data will be subject to statistical monitoring and at least 10% of data 
will be subjected to on-site monitoring.  
Investigators/institutions are required to provide direct access to source data/documents for trial-related monitoring, 
audits, ethics committee review and regulatory inspection. All trial related and source documents must be kept for 
five years after the end of the trial. 
 
2.14 END OF TRIAL FOR PARTICIPANTS 
 
The trial ends either at death, discharge, or six weeks post-randomisation, whichever occurs first. If during the 
treatment phase a woman develops an adverse event the trial drug should be stopped, woman treated in line with 
local procedures and then followed up. 
 
The trial may be terminated early by the Trial Steering Committee (TSC). The DMC may give advice/recommendation 
for the early termination of the trial but the TSC is responsible for the final decision.  
 
2.15 ANALYSIS 
 
The main analyses will compare all those allocated antifibrinolytic treatment versus those allocated placebo, on an 
‘intention to treat’ basis, irrespective of whether they received the allocated treatment or not. Results will be 
presented as appropriate effect estimates with a measure of precision (95% confidence intervals).  Subgroup analyses 
for the primary outcome will be based on type of delivery (vaginal or caesarean section); administration or not of 
prophylactic uterotonics; and on whether the clinical decision to consider trial entry was based primarily on estimated 
blood loss alone or on haemodynamic instability.  Interaction test will be used to test whether the effect of treatment 
(if any) differs across these subgroups.  Between-sites heterogeneity in effectiveness will be explored.  All analyses will 
be conducted in STATA. A detailed Statistical Analysis Plan setting out full details of the proposed analyses will be 
finalised before the trial database is locked for final analysis. 
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3 TRIAL ORGANISATION AND RESPONSIBILITIES       
 
3.1 SPONSORSHIP AND TRIAL MANAGEMENT  
 
The WOMAN Trial is sponsored by the London School of Hygiene & Tropical Medicine (LSHTM) and its responsibilities 
coordinated by the Trial Coordinating Centre (TCC).  The TCC may delegate responsibilities to third parties which will 
be outlined in relevant agreements. The responsibilities of the TCC will be overseen by the Trial Management Group. 
 
3.2 INDEMNITY 
 
LSHTM accepts responsibility attached to its sponsorship of the trial and, as such, would be responsible for claims for 
any non-negligent harm suffered by anyone as a result of participating in this trial. The indemnity is renewed on an 
annual basis and LSHTM assures that it will continue renewal of the indemnity for the duration of this trial.  
 
3.3 PROTOCOL DEVELOPMENT 
The Protocol Committee consists of the following investigators who will be responsible for the development of and 
agreeing to the final protocol. Subsequent changes to the final Protocol will require the agreement of the Trial 
Steering Committee. 
 
CHIEF INVESTIGATOR CLINICAL EXPERTS  
Professor Ian Roberts  
Trials Coordinating Centre 
London School of Hygiene & Tropical Medicine 
Keppel Street, London WC1E 7HT, UK 
Email: Ian.Roberts@Lshtm.ac.uk 
Professor Zarko Alfirevic  
Division of Perinatal and Reproductive Medicine 
University of Liverpool 
Liverpool Women's Hospital 
Crown Street, Liverpool L8 7SS, UK 
Email: zarko@Liv.ac.uk 
TRIAL MANAGEMENT Dr Metin Gülmezoglu 
Department of Reproductive Health and Research 
World Health Organization 
Avenue Appia 20, CH-1211 Geneva 27, Switzerland 
Email: gulmezoglum@who.int 
Ms Haleema Shakur, Senior Lecturer 
Trials Coordinating Centre 
London School of Hygiene & Tropical Medicine 
Keppel Street, London WC1E 7HT, UK 
Email: Haleema.Shakur@Lshtm.ac.uk 
STATISTICIAN Professor Carine Ronsmans 
Infectious Diseases Epidemiology Unit 
London School of Hygiene & Tropical Medicine 
Keppel Street, London WC1E 7HT, UK 
Email: Carine.Ronsmans@Lshtm.ac.uk 
Professor Diana Elbourne 
Medical Statistics Unit 
London School of Hygiene & Tropical Medicine 
Keppel Street, London WC1E 7HT, UK 
Email: Diana.Elbourne@Lshtm.ac.uk 
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3.4 INDEPENDENT DATA MONITORING COMMITTEE (DMC) 
 
Membership: 
NAME AFFILIATION EXPERTISE 
Professor Sir Iain Chalmers James Lind Initiative, Oxford, UK 
Large scale randomised controlled trials; 
Obstetric care 
Professor Pisake Lumbiganon 
Professor of Obstetrics & Gynaecology; 
Convenor, Thai Cochrane Network; 
Faculty of Medicine, Khon Kaen 
University, Thailand 
Obstetric care 
Dr Gilda Piaggio Statistika Consultoria, São Paulo, Brazil 
Statistician (Extensive experience of 
reproductive health and research at the 
World Health Organization) 
 
Mortality and severe morbidity is expected within the target population. To provide protection for study participants, 
an independent DMC has been appointed for this trial to oversee the safety monitoring. The DMC will review on a 
regular basis accumulating data from the ongoing trial and advise the Trial Steering Committee regarding the 
continuing safety of current participants and those yet to be recruited, as well as reviewing the validity and scientific 
merit of the trial. 
 
The DMC composition, name, title and address of the chairman and of each member, will be given in the DMC Charter 
which will be in line with that proposed by the DAMOCLES Study Group.33  Membership includes expertise in the 
relevant field of study, statistics and research study design. The DMC Charter includes, but is not limited to, defining: 
(a) the schedule and format of the DMC meetings 
(b) the format for presentation of data 
(c) the method and timing of providing interim reports  
(d) stopping rules 
 
Standard Operating Procedures: The Data Monitoring Committee (DMC) has the responsibility for deciding whether, 
while randomisation is in progress, the unblinded results (or the unblinded results for a particular subgroup), should 
be revealed to the TSC. The DMC Charter states that they will do this if, and only if, two conditions are satisfied:  
(1) the results provide proof beyond reasonable doubt that treatment is on balance either definitely harmful or 
definitely favourable for all, or for a particular category of, participants in terms of the major outcome; (2) The results, 
if revealed, would be expected to substantially change the prescribing patterns of clinicians who are already familiar 
with any other trial results that exist. Exact criteria for “proof beyond reasonable doubt” are not, and cannot be, 
specified by a purely mathematical stopping rule, but they are strongly influenced by such rules. DMC Charter is in 
agreement with the Peto-Haybittle34,35 stopping rule whereby an interim analysis of major endpoint would generally 
need to involve a difference between treatment and control of at least three standard errors to justify premature 
disclosure. An interim subgroup analysis would, of course, have to be even more extreme to justify disclosure. This 
rule has the advantage that the exact number and timing of interim analyses need not be pre-specified. In summary, 
the stopping rules require extreme differences to justify premature disclosure and involve an appropriate combination 
of mathematical stopping rules and scientific judgment. 
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3.5 TRIAL STEERING COMMITTEE  
Membership: 
NAME AFFILIATION EXPERTISE 
Professor Adrian Grant 
(Chair) 
Director, Health Services Research Unit, 
University of Aberdeen 
Health Services Research; Randomised 
Control Trials 
Professor Ian Roberts  
(Principal Investigator) 
London School of Hygiene & Tropical 
Medicine 
Epidemiology; Randomised Control Trials; 
Conduct of large scale international trials 
Dr Metin Gülmezoglu 
Dr Metin Gülmezoglu 
World Health Organization, Geneva 
Obstetrician; Co-ordinating Editor of the 
WHO Reproductive Health Library; 
Randomised Control Trials 
Dr Kaosar Afsana BRAC Health Programme, Bangladesh 
Reproductive & Sexual Health & Rights; 
Rural and Urban Maternal, Neonatal and 
Child Health Programme in BRAC 
Dr Oladapo Olayemi 
University College Hospital, Ibadan, 
Nigeria 
Consultant Obstetrician; perspective on 
obstetrics in a developing country 
Professor Beverley Hunt Kings College, London 
Professor of Thrombosis & Haemostasis, 
Randomised Control Trials 
 
The role of the Trial Steering Committee (TSC) is to provide overall supervision of the trial.  In particular, the TSC will 
concentrate on the progress of the trial, adherence to the protocol, patient safety and consideration of new 
information.  The TSC must be in agreement with the final Protocol and, throughout the trial, will take responsibility 
for: 
(a) major decisions such as a need to change the protocol for any reason 
(b) monitoring and supervising the progress of the trial 
(c) reviewing relevant information from other sources 
(d) considering recommendations from the DMC 
(e) informing and advising the Trial Management Group on all aspects of the trial 
 
The steering committee consists of experienced obstetric experts, clinical trialists as well as a Reproductive & Sexual 
Health & Rights representative.  Face to face meetings will be held at regular intervals determined by need, but no less 
than once a year.  A TSC Charter will be agreed at the first meeting which will detail how it will conduct its business. 
 
When outcome data are available for 1,000 trial participants, the TSC will review the rate of recruitment into the trial 
and the overall event rates. The TSC will consider the extent to which the rate of recruitment and the event rates 
correspond to those anticipated before the trial and will take whatever action is needed in light of this information. 
 
3.6 COLLABORATORS’ RESPONSIBILITIES 
 
Coordination within each participating hospital will be through a local Principal Investigator whose responsibility will 
be detailed in an agreement in advance of starting the trial and will include:  
 Ensure all necessary approvals are in place prior to starting the trial 
 Delegate trial related responsibilities only to suitably trained and qualified personnel 
 Train relevant medical and nursing staff who see obstetric patients and ensure that they remain aware of the 
state of the current knowledge, the trial and its procedures (there are wall charts, pocket summaries and a set of 
slides to assist with this)  
 Agree to comply with the final trial protocol and any relevant amendments 
 Ensure that all women with postpartum haemorrhage are considered promptly for the trial 
 Ensure consent is obtained in line with local approved procedures 
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 Ensure that the patient entry and outcome data are completed and transmitted to the TCC in a timely manner 
 Ensure the Investigator’s Study File is up-to-date and complete 
 Ensure all Adverse Events are reported promptly to the TCC 
 Accountability for trial treatments at their site 
 Ensure the trial is conducted in accordance with ICH GCP and fulfils all national and local regulatory requirements 
 Allow access to source data for monitoring, audit and inspection 
 Be responsible for archiving all original trial documents including the data forms for five years after the end of 
the trial 
 
3.7 TRIAL MANAGEMENT GROUP (TMG) AND TRIAL COORDINATING CENTRE (TCC) 
RESPONSIBILITIES  
 
 The Trial Management Group will consist of the Protocol Committee members (Section 3.3) plus a trial manager, 
data manager and trial administrator.  
 The TCC will act on behalf of the Sponsor and will be responsible to the TMG to ensure that all Sponsor’s 
responsibilities are carried out.   The responsibilities will include (but not limited to): 
o Report to the Trial Steering Committee 
o Maintain the Trial Master File 
o Identify trial sites 
o Confirm  all approvals are in place before release of the trial treatment and the start of the trial at a site   
o Provide training about the trial 
o Provide study materials 
o Data management centre 
o 24-hour advice and unblinding service 
o Give collaborators regular information about the progress of the study 
o Respond to any questions (e.g. from collaborators) about the trial 
o Ensure data security and quality and observe data protection laws 
o Safety reporting  
o Ensure trial is conducted in accordance with the ICH GCP 
o Statistical analysis 
o Publication of trial results  
 
3.8 CONTACTING THE TCC IN AN EMERGENCY  
 
For urgent enquiries, adverse event reporting and unblinding queries investigators can contact the 24-hour telephone 
service provided by the TCC.  A central telephone number is given in the Investigator’s Study File and posters.   
 
3.9 PUBLICATION AND DISSEMINATION OF RESULTS 
 
All efforts will be made to ensure that the trial protocol and results arising from the WOMAN trial are published in an 
established peer-reviewed journal.  At least one publication of the main trial results will be made.  All publications will 
follow relevant external guidance such as the ‘Uniform Requirements for Submission of Manuscripts to Biomedical 
Journals’ issued by the International Committee of Medical Journal Editors (ICMJE) (2008 update) and the CONSORT 
statement.36,37  Links to the publication will be provided in all applicable trial registers. Dissemination of results to 
patients will take place via the media, trial website (www.thewomantrial@Lshtm.ac.uk) and relevant patient 
organisations. Collaborating investigators will play a vital role in disseminating the results to colleagues and patients.    
The success of the trial will be dependent entirely upon the collaboration of midwives, nurses and doctors in the 
participating hospitals and those who hold key responsibility for the trial.  Hence, the credit for the study will be 
assigned to the key collaborator(s) from a participating site as it is crucial that those taking credit for the work have 
actually carried it out. The results of the trial will be reported first to trial collaborators.  
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3.10 FINANCIAL SUPPORT 
 
The run-in costs for this trial and up to 2,000 patients' recruitment were funded by LSHTM. Funding to complete the 
recruitment of 15,000 patients is provided by the Health Innovation Challenge Fund (Wellcome Trust and Department 
of Health, UK). The recruitment of the additional 5,000 patients as well as dissemination and implementation planning 
is funded by Bill and Melinda Gates Foundation. Funding for this trial covers meetings and central organisational costs 
only. Pfizer, the manufacturer of tranexamic acid, have provided the funding for the trial drug and placebo used for 
this trial. The design and management of the study are entirely independent of the manufacturers of tranexamic acid, 
which is not a new product. 
 
Large trials of such drugs, involving many hospitals, are important for future patients, but are practicable only if those 
collaborating in them do so without payment (except for recompense of any minor local costs that may arise). 
Agreement for repayment of local costs will be made in advance.  
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 4 ABBREVIATIONS USED 
 
 
  
AE Adverse Event 
AR Adverse Reaction 
CONSORT CONsolidated Standards of Reporting Trials 
CRF Case Report Form 
DMC Data Monitoring Committee 
DVT Deep Vein Thrombosis 
FG  French Gauge 
GCP Good Clinical Practice 
HELLP Hemolytic anemia, Elevated Liver enzymes and Low Platelet count 
HPLC  High Performance Liquid Chromatography 
HRQoL  Health Related Quality of Life 
ICH GCP International Conference on Harmonisation of Good Clinical Practice 
ICMJE  International Committee for Medical Journal Editors 
kg Kilogram 
LSHTM London School of Hygiene & Tropical Medicine 
MDG Millennium Development Goal 
mg Milligram 
mL Millilitre 
PeR Personal Representative 
PPH Postpartum Haemorrhage 
PrR Professional Representative 
PSF  Product Specification File 
QP Qualified person 
SAE Serious Adverse Event 
SAR Serious Adverse Reaction 
SUSAR Suspected Unexpected Serious Adverse Reaction 
TCC Trials Coordinating Centre 
TMG Trial Management Group 
TSC Trial Steering Committee 
TXA Tranexamic Acid 
UK United Kingdom 
VAS  Visual Analogue Score 
WHO World Health Organisation 
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Appendix 1: Entry form 
Appendix 2: Outcome form  
Appendix 3: Country/site specific documents 
a) Brief information leaflet for pregnant women & family 
b) Consent procedure overview 
c) Information sheet for woman and her representative 
d) Informed consent form for woman 
e) Informed consent form for representative 
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Consent procedure overview 
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Information sheet for woman and her representative, page 1 
(HOSPITAL LETTERHEAD) 
INFORMATION SHEET FOR THE PATIENT AND HER REPRESENTATIVE(S) 
THE WOMAN TRIAL 
TITLE OF RESEARCH: TRANEXAMIC ACID FOR THE TREATMENT OF POSTPARTUM HAEMORRHAGE: AN 
INTERNATIONAL RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL 
TRIAL SITE NUMBER: [ID from database] 
LEAFLET VERSION: VERSION 1.0 DATED: 11 MAY 2009 
This hospital is taking part in an international research study to find ways to improve the 
treatment of women who have severe bleeding after delivery of their baby.   
(1) We would like to invite you to take part in this study 
(2) When you were very unwell you were included in this study and we would like you to 
continue to take part 
(3) As a representative of the patient we are asking you to make a decision on her behalf 
(Please circle the option that applies) 
 
The Research Doctor has already checked to make sure you/the patient is medically suitable for 
this research and you are being asked to make a decision about whether you/the patient can be 
included in this study. This sheet gives information about the study, including the reasons why the 
study is being done, and the risks and benefits of taking part. 
 
PLEASE READ THE INFORMATION BELOW CAREFULLY AND ASK THE DOCTOR OR MIDWIFE 
LOOKING AFTER YOU ANY QUESTIONS YOU MAY HAVE. 
 
1) What is the purpose of the study? 
In this hospital, women who have a very severe bleeding after childbirth (also called 
postpartum haemorrhage) are given the best available treatments.  The aim of this 
research study is to see if there is a better treatment for women who have severe bleeding 
after childbirth.  We hope that the treatment (tranexamic acid) will help the blood to clot 
sooner, and so lessen the amount of blood lost and reduce the need for a blood 
transfusion and other treatments.  But it is also possible that the study treatment may 
cause clots where they are not needed, and because the drug is not routinely used after 
childbirth, we do not know all the likely side effects.  We hope to find that the treatment 
will do a little more good than harm but we don’t yet know this. 
 
2) Why is this research being done? 
Postpartum haemorrhage can be a very serious condition and sometimes requires surgery 
to control the bleeding.  Many thousands of women worldwide die each year from this 
condition and it is important to find better ways of controlling excessive bleeding after 
childbirth.  
 
Tranexamic acid is often used to reduce bleeding after major operations such as heart 
operations.  Some women who have heavy menstrual bleeding (periods) also use 
tranexamic acid.  The WOMAN study is being done to see if TXA can reduce bleeding in 
women with postpartum bleeding. 
  
Page 33 of 36 
Version 1.1 Protocol ISRCTN76912190 Version date: 31 January 2014 
Information sheet for woman and her representative, page 2 
 
3) Why have you been invited? 
You have been diagnosed with postpartum haemorrhage by your doctor.  Your doctor has 
checked that you are suitable for the study, but it is up to you whether or not you decide to 
take part. 
 
4) Who is doing the study and who can you call if you have any questions or 
problems? 
Dr _____________________________ is in charge of this study at this hospital.  The study 
is coordinated by doctors and a trial team at The London School of Hygiene & Tropical 
Medicine (University of London).  If you have any questions you can contact the doctor at: 
Address:  
Telephone:   
You are also free to visit the trial website to keep up to date with the progress of the trial: 
www.thewomantrial.Lshtm.ac.uk 
 
5) A patient cannot be in this study if: 
 The doctor thinks there is a particular reason why tranexamic acid definitely should not be given 
 The doctor thinks there is a particular reason why tranexamic acid definitely should be given 
 They are not an adult 
 
6) What will happen/has happened during this study? 
You will be given all the usual emergency treatments for severe bleeding after childbirth, 
including fluids to replace the blood that you have lost.  You will also be given a dose of 
either the tranexamic acid or a placebo (a liquid which doesn’t contain tranexamic acid).  
This dose will be given as an injection into your vein.  If after about 30 minutes you are still 
bleeding, or if the bleeding stops and starts again within 24 hours after the first dose, you 
may be given a second dose of the same. You will not receive more than two injections for 
the study.  
 
We do not know whether giving tranexamic acid on top of all the other treatments will 
help or not, so half the women in the study will receive tranexamic acid and the other half 
will receive a placebo.  The choice of which treatment you receive is completely random 
and you will have an equal chance of receiving either one.  Neither you nor the doctor 
treating you will know which treatment you receive.  This information is kept on a 
confidential list at an independent location in London.  The study involves no extra tests 
but your doctor/midwife will send brief details about your treatment and recovery to the 
Coordinating Centre in London.  They will also send information about the health of your 
baby/ies.  If after discharge from hospital and up to 42 days after treatment you develop 
any medical problems, please let the doctor named on this form know.  This information 
will be used in strict confidence by the people working on the study and will not be 
released under any circumstances. 
 
7) What are the possible risks of being in the study? 
Tranexamic acid is NOT a new drug and it is widely used to reduce bleeding in conditions 
such as major heart surgery.  There is no conclusive evidence of serious side effects with 
short term use.  But the study treatment may cause clots where they are not needed and,  
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 because the drug is not routinely used after childbirth, we do not know all the likely side 
effects.  Your doctor will report to the trial organisers any unexpected problems you may 
have. 
 
8) What are the possible benefits of being in the study? 
We hope that tranexamic acid may help reduce blood loss.  The knowledge that we gain 
from this study will help women with postpartum haemorrhage worldwide in the future. 
  
9) What information do we keep private? 
All information about you and the reason for bleeding after childbirth will be kept private.  
The only people allowed to look at the information will be the doctors who are running the 
study, the staff at the Coordinating Centre and the regulatory authorities who check that 
the study is being carried out correctly.  The Trial Coordinating Centre may want to collect 
or copy some trial documents which will have your name and will include the signed 
Consent Form.  This will help them to ensure that the trial is being carried out correctly.  
Your details will remain confidential and will be held in secure storage at the Trial 
Coordinating Centre.  Your confidential information will be kept separately from the trial 
data and will be destroyed within five years of the trial ending. We will publish the results 
of the study in a medical journal so that other doctors can benefit from the knowledge, but 
your personal information will NOT be included and there will be no way that you can be 
identified.  
 
10) Can you change your mind about being in the study? 
You can always withdraw from the study at any time.  You just need to say for example 
“I’ve decided I don’t want to be in this study now”.  We hope that you will let us use 
information about how you got on, but if you do not want us to use it please tell the 
doctor.  
 
11) What else do you need to know? 
 In the event that something does go wrong and you are harmed during the study, the 
London School of Hygiene & Tropical Medicine who are organising the study would be 
responsible for claims for any non-negligent harm suffered as a result of participating in 
this study.  
 We will ask you to sign a separate consent form and give you a copy to keep and you can 
also keep this information sheet.  
 This study has been reviewed and approved by a Research Ethics Committee. 
 
12) What happens afterwards? 
If after you leave this hospital you develop any problems at any time up to 42 days after 
you had your baby, we would definitely want to know about it.  You will be given a card 
with the contact details of the research doctor at this hospital, which you should keep 
safely and show to anyone who may be treating you for any illness. 
 
If you would like to have a copy of the final results of this study, please let the research 
doctor know and s/he will ensure you receive a copy when it is published.  
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